Non-toxic melanoma therapy by a novel tubulin-binding agent
about
Potent anti-inflammatory activity of novel microtubule-modulating brominated noscapine analogsRational design, synthesis, and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agentsA novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering.A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells.Drugs that target dynamic microtubules: a new molecular perspectiveSynergistic antimicrotubule therapy for prostate cancerSecond generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluationNoscapine recirculates enterohepatically and induces self-clearance.Chemoprevention of familial adenomatous polyposis by bromo-noscapine (EM011) in the Apc(Min/+) mouse model.Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cellsA novel microtubule-modulating agent EM011 inhibits angiogenesis by repressing the HIF-1α axis and disrupting cell polarity and migrationDetermination of the optimal tubulin isotype target as a method for the development of individualized cancer chemotherapyInvestigation of Targetin, a Microtubule Binding Agent which Regresses the Growth of Pediatric High and Low Grade Gliomas.In-Vitro and Ex-Vivo Investigations of the Microtubule Binding Drug Targetin on Angiogenesis.In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin).
P2860
Q28472843-EE51E6BA-403B-44B5-8925-F928361D3830Q28534566-DE5F7397-A17B-463D-90AE-1608A1CFCD53Q30502330-B63B6C7D-60AE-4967-9973-9B36B0EB20A0Q33905704-DEA6FB07-7227-4731-9525-39AA640E63A2Q35163252-4DB0F410-CBA8-4352-B6E6-CE933A62CAECQ35168819-8E684A19-9F00-4E58-92F4-084801783774Q35231775-D7DE4577-A34F-443B-BB9E-977A01C6C8C9Q35893886-391BF5E4-EAA3-4584-9E22-9641CB77C588Q35996030-D7EE1FB0-FE52-43FB-8C05-13959153BB02Q36191591-A551F4BB-6E7C-4A6C-B4CE-2E47C96E48E2Q36447016-FDEA096C-C1BD-4BB9-AF95-B51651772C0AQ36836578-7FF696BB-9E70-4FFD-B516-FAC4F90E3546Q37709935-2880E322-7E5D-4344-A7D9-0CF46A94793DQ37709945-E68E7EF3-A0FC-4530-8281-E93AF97A0E13Q39428478-A60F7008-A16C-4895-AD71-0A02FD98C7B6
P2860
Non-toxic melanoma therapy by a novel tubulin-binding agent
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Non-toxic melanoma therapy by a novel tubulin-binding agent
@ast
Non-toxic melanoma therapy by a novel tubulin-binding agent
@en
type
label
Non-toxic melanoma therapy by a novel tubulin-binding agent
@ast
Non-toxic melanoma therapy by a novel tubulin-binding agent
@en
prefLabel
Non-toxic melanoma therapy by a novel tubulin-binding agent
@ast
Non-toxic melanoma therapy by a novel tubulin-binding agent
@en
P2093
P2860
P356
P1476
Non-toxic melanoma therapy by a novel tubulin-binding agent
@en
P2093
Anshumali Awasthi
Harish C Joshi
Jonathan D Glass
Neerupma Dhiman
Padmashree C G Rida
Ritu Aneja
Seneshaw Asress
Sudarshan K Arora
P2860
P304
P356
10.1002/IJC.24765
P50
P577
2010-01-01T00:00:00Z